Evidence map›Paper›PMID 30470967›Full record

ReviewJournal of thrombosis and thrombolysis2019

Direct oral anticoagulants in the early phase of non valvular atrial fibrillation-related acute ischemic stroke: focus on real life studies.

Luca Masotti, Elisa Grifoni, Alessandro Dei, Vieri Vannucchi, Federico Moroni, Grazia Panigada, Stefano Spolveri, Giancarlo Landini

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of thrombosis and thrombolysis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Luca MasottiInternal Medicine II, Stroke Unit and Center of Thromboembolic Diseases, San Giuseppe Hospital, Viale Boccaccio 20, 50053, Empoli, Florence, Italy. luca.masotti@tin.it.
Elisa GrifoniInternal Medicine II, Stroke Unit and Center of Thromboembolic Diseases, San Giuseppe Hospital, Viale Boccaccio 20, 50053, Empoli, Florence, Italy.
Alessandro DeiInternal Medicine II, Stroke Unit and Center of Thromboembolic Diseases, San Giuseppe Hospital, Viale Boccaccio 20, 50053, Empoli, Florence, Italy.
Vieri VannucchiInternal Medicine, Stroke Unit and Center of Thromboembolic Diseases, Santa Maria Nuova Hospital, Florence, Italy.
Federico MoroniInternal Medicine, Stroke Unit and Center of Thromboembolic Diseases, Santa Maria Nuova Hospital, Florence, Italy.
Grazia PanigadaInternal Medicine and Stroke Unit, SS. Cosma and Damiano Hospital, Pescia, Pistoia, Italy.
Stefano SpolveriInternal Medicine and Stroke Unit, Borgo San Lorenzo Hospital, Florence, Italy.
Giancarlo LandiniInternal Medicine, Stroke Unit and Center of Thromboembolic Diseases, Santa Maria Nuova Hospital, Florence, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Strong evidence for the use of direct oral anticoagulants (DOACs) in the early phase of non valvular atrial fibrillation (NVAF)-related acute ischemic stroke (AIS) is lacking, because this kind of patients were excluded from phase III randomized clinical trials (RCT) and ad hoc RCTs are ongoing. In the latest years a lot of real life studies on this topic have been published. The aim of our review was to focus on these. We reviewed the PubMed databases searching articles reporting on DOACs starting time within 2 weeks from AIS onset. We selected fifteen studies, eight with retrospective, six with prospective observational and one with a prospective, open-label, single arm design. Overall, 2920 patients (47.8% females) were included. In twelve studies median or mean age of patients was over 75 years. Mean or median NIHSS ad hospital admission was ≤ 12 in all studies. About one-third of patients (32.4%) received urgent reperfusion by systemic thrombolysis or mechanical thrombectomy. About one-fifth of patients (22.8%) had large infarct size. Median starting time of DOACs was reported in thirteen studies and it ranged from 2 to 8 days. About one-half of patients (45.9%) received a low dose of DOACs. In studies reporting on median or mean CHA

Indexed as

Administration, OralAgedAged, 80 and overAnticoagulantsAtrial FibrillationBrain IschemiaDrug Administration ScheduleFemaleHemorrhageHumansIschemic Attack, TransientMaleMiddle AgedRecurrenceRisk FactorsSecondary PreventionAnticoagulantsApixabanDabigatranDirect oral anticoagulantsEdoxabanRivaroxabanStroke

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.